NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M€, AND ALSO COMMITS TO A LOCK-UP
June 29 2023 - 11:45AM
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL
UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF
0.5M€, AND ALSO COMMITS TO A LOCK-UP
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S
CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND
PAYMENT OF 0.5M€, AND ALSO COMMITS TO A LOCK-UP
NFL BIOSCIENCES (Euronext Growth Paris –
FR0014003XT0 – ALNFL), a biopharmaceutical company
developing botanical medicines for the treatment of
drug dependencies and addictions, has been
informed of the exercise of 100,000 share subscription warrants
("BSA") held by GB Holding, the holding company of
Mr Gérard Leduc, resulting in the creation
of 1,000,000 new shares. As of
June 29, 2023, GB Holding holds
850,000 shares, representing 11.17% of NFL Biosciences'
capital, and has undertaken to retain all shares held to date
for a period of 9 months
minimum.
Gérard Leduc is a well-known entrepreneur in the
pharmaceutical sector, having founded, managed and sold Ethypharm,
a European pharmaceutical laboratory specializing in Central
Nervous System (CNS) pathologies and Hospital Injectables, with
over 800 employees. Since July 2018, GB Holding has held 100,000
warrants, exercisable until July 2, 2023 at a price of €0.50 per
share, with each warrant giving the right to subscribe 10 shares
with a par value of €0.03 each. The exercise of these warrants
represents a cash contribution of €0.5 million to the Company,
giving rise to the issuance of 1,000,000 new shares. GB Holding has
given Invest Securities a lock-up commitment with respect to
850,000 shares subscribed on exercise of the warrants, for a period
of 9 months following the settlement-delivery date of the new
shares, i.e. until March 31, 2024. The new shares were issued today
by the Company, and will have the same rights as the existing
shares (ISIN code FR0014003XT0).
When exercising his warrants,
Mr Leduc
declared "I'm delighted to continue contributing
to the success of NFL Biosciences. Products to treat drug
addictions have always been of great interest to me. NFL-101, for
smoking cessation, is a potentially revolutionary product with a
completely new mechanism of action. It could change the way this
addiction has been treated until now".
Ignacio Faus, Chairman
of the Board and CEO of NFL
Biosciences said, "Mr. Leduc has
been supporting the company from its outset by participating in the
company's first fundraising round. Today, we believe that his
decision to exercise his BSAs and retain his NFL Biosciences shares
is proof of his confidence in the potential of our drug candidates
and in particular NFL-101 for smoking cessation, for which the
first results of the two ongoing clinical studies are expected in
Q3 and Q4 2023”.
Following the exercise of the stock warrants
held by GB Holding, the share capital of NFL Biosciences has
increased to 7,606,769 shares, compared with 6,606,769 prior to the
exercise.
The detailed characteristics of the capital
structure and potential capital structure prior to the exercise of
the warrants are indicated in the 2022 Annual Financial Report made
available on April 28, 2023 and available on the "Documentation"
page of the Company's website: https://www.nflbiosciences.com.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative. NFL Biosciences is also developing
NFL-301, a natural drug candidate for the reduction of alcohol
consumption and has a drug development project for the treatment of
cannabis use disorder.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contacts
Bruno Lafont – info@nflbiosciences.com - +33 4
11 93 76 67 Agence
Calyptus – nflbiosciences@calyptus.net - +33 1 53 65 68 6
-
NFLBiosciences_CP_Exercice-BSA-Gerard-LEDUC_20230629_Final_ENG
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Mar 2024 to Apr 2024
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Apr 2023 to Apr 2024
